In vivo dosimetry during external photon beam radiotherapy

In vivo dosimetry by an aSi-based EPID

A method for the in vivo determination of the isocenter dose, Diso, and mid-plane dose, Dm, using the transmitted signal St measured by 25 central pixels of an aSi-based EPID is here reported. The method has been applied to check the conformal radiotherapy of pelvic tumors and supplies accurate in vivo dosimetry avoiding many of the disadvantages associated with the use of two diode detectors (at the entrance and exit of the patient) as their periodic recalibration and their positioning. Irradiating water-equivalent phantoms of different thicknesses, a set of correlation functions F(w, l) were obtained by the ratio between St and Dm as a function of the phantom thickness, w, for a different field width, l. For the in vivo determination of Diso and Dm values, the water-equivalent thickness of the patients (along the beam central axis) was evaluated by means of the treatment planning system that uses CT scans calibrated in terms of the electron densities. The Diso and Dm values experimentally determined were compared with the stated doses D(iso,TPS) and D(m,TPS), determined by the treatment planning system for ten pelvic treatments. In particular, for each treatment four fields were checked in six fractions. In these conditions the agreement between the in vivo dosimetry and stated doses at the isocenter point were within 3%. Comparing the 480 dose values obtained in this work with those obtained for 30 patients tested with a similar method, which made use of a small ion-chamber positioned on the EPIDs to obtain the transmitted signal, a similar agreement was observed. The method here proposed is very practical and can be applied in every treatment fraction, supplying useful information about eventual patient dose variations due to the incorrect application of the quality assurance program based on the check of patient setup, machine setting, and calculations.

Clinical implementation of MOSFET detectors for dosimetry in electron beams

BACKGROUND AND PURPOSE

To determine the factors converting the reading of a MOSFET detector placed on the patient's skin without additional build-up to the dose at the depth of dose maximum (D(max)) and investigate their feasibility for in vivo dose measurements in electron beams.

MATERIALS AND METHODS

Factors were determined to relate the reading of a MOSFET detector to D(max) for 4 - 15 MeV electron beams in reference conditions. The influence of variation in field size, SSD, angle and field shape on the MOSFET reading, obtained without additional build-up, was evaluated using 4, 8 and 15 MeV beams and compared to ionisation chamber data at the depth of dose maximum (z(max)). Patient entrance in vivo measurements included 40 patients, mostly treated for breast tumours. The MOSFET reading, converted to D(max), was compared to the dose prescribed at this depth.

RESULTS

The factors to convert MOSFET reading to D(max) vary between 1.33 and 1.20 for the 4 and 15 MeV beams, respectively. The SSD correction factor is approximately 8% for a change in SSD from 95 to 100 cm, and 2% for each 5-cm increment above 100 cm SSD. A correction for fields having sides smaller than 6 cm and for irregular field shape is also recommended. For fields up to 20 x 20 cm(2) and for oblique incidence up to 45 degrees, a correction is not necessary. Patient measurements demonstrated deviations from the prescribed dose with a mean difference of -0.7% and a standard deviation of 2.9%.

CONCLUSION

Performing dose measurements with MOSFET detectors placed on the patient's skin without additional build-up is a well suited technique for routine dose verification in electron beams, when applying the appropriate conversion and correction factors.

Accurate two-dimensional IMRT verification using a back-projection EPID dosimetry method

The use of electronic portal imaging devices (EPIDs) is a promising method for the dosimetric verification of external beam, megavoltage radiation therapy-both pretreatment and in vivo. In this study, a previously developed EPID back-projection algorithm was modified for IMRT techniques and applied to an amorphous silicon EPID. By using this back-projection algorithm, two-dimensional dose distributions inside a phantom or patient are reconstructed from portal images. The model requires the primary dose component at the position of the EPID. A parametrized description of the lateral scatter within the imager was obtained from measurements with an ionization chamber in a miniphantom. In addition to point dose measurements on the central axis of square fields of different size, we also used dose profiles of those fields as reference input data for our model. This yielded a better description of the lateral scatter within the EPID, which resulted in a higher accuracy in the back-projected, two-dimensional dose distributions. The accuracy of our approach was tested for pretreatment verification of a five-field IMRT plan for the treatment of prostate cancer. Each field had between six and eight segments and was evaluated by comparing the back-projected, two-dimensional EPID dose distribution with a film measurement inside a homogeneous slab phantom. For this purpose, the y-evaluation method was used with a dose-difference criterion of 2% of dose maximum and a distance-to-agreement criterion of 2 mm. Excellent agreement was found between EPID and film measurements for each field, both in the central part of the beam and in the penumbra and low-dose regions. It can be concluded that our modified algorithm is able to accurately predict the dose in the midplane of a homogeneous slab phantom. For pretreatment IMRT plan verification, EPID dosimetry is a reliable and potentially fast tool to check the absolute dose in two dimensions inside a phantom for individual IMRT fields. Film measurements inside a phantom can therefore be replaced by EPID measurements.

An analysis of an implantable dosimeter system for external beam therapy

BACKGROUND AND PURPOSE

To review the data from an implantable radiation dosimetry system used in a clinical setting and to examine correlations between dosimeter readings and potential causative error sources.

MATERIALS AND METHODS

MOSFET (metal oxide semiconductor field effect transistor) based encapsulated dosimeters were evaluated in a phantom (in vitro) and in a study with 18 patients. The dosimeters were placed in the gross tumor volume or in collateral normal tissue. Predicted dose values were established by imaging the dosimeters in the planning CTs.

RESULTS

The in vitro study confirmed that bounding cumulative errors due to setup, planning, and machine output within a +/-5% level is achievable. In patients, it was found that deviations from the targeted dose often exceeded the 5% level.

CONCLUSIONS

The use of an implantable dosimeter system could provide an effective empiric check on the dose delivered at depth. Such a tool may have value for institutional quality assurance, as well as for therapy delivered to individual patients.

Experimental verification of a portal dose prediction model

Electronic portal imaging devices (EPIDs) can be used to measure a two-dimensional (2D) dose distribution behind a patient, thus allowing dosimetric treatment verification. For this purpose we experimentally assessed the accuracy of a 2D portal dose prediction model based on pencil beam scatter kernels. A straightforward derivation of these pencil beam scatter kernels for portal dose prediction models is presented based on phantom measurements. The model is able to predict the 2D portal dose image (PDI) behind a patient, based on a PDI without the patient in the beam in combination with the radiological thickness of the patient, which requires in addition a PDI with the patient in the beam. To assess the accuracy of portal dose and radiological thickness values obtained with our model, various types of homogeneous as well as inhomogeneous phantoms were irradiated with a 6 MV photon beam. With our model we are able to predict a PDI with an accuracy better than 2% (mean difference) if the radiological thickness of the object in the beam is symmetrically situated around the isocenter. For other situations deviations up to 3% are observed for a homogeneous phantom with a radiological thickness of 17 cm and a 9 cm shift of the midplane-to-detector distance. The model can extract the radiological thickness within 7 mm (maximum difference) of the actual radiological thickness if the object is symmetrically distributed around the isocenter plane. This difference in radiological thickness is related to a primary portal dose difference of 3%. It can be concluded that our model can be used as an easy and accurate tool for the 2D verification of patient treatments by comparing predicted and measured PDIs. The model is also able to extract the primary portal dose with a high accuracy, which can be used as the input for a 3D dose reconstruction method based on back-projection.

Initial clinical results of an in vivo dosimeter during external beam radiation therapy

PURPOSE

An implantable radiation dosimeter has been developed to monitor dose delivered at depth in patients undergoing external beam therapy. A clinical pilot study was conducted to test the safety, efficacy, and utility of the device.

METHODS AND MATERIALS

Ten patients, all with unresectable malignant disease, were enrolled to assess implantation risk and movement of the device in the body and to compare the in vivo measured dose to the value predicted by the treatment planning system software.

RESULTS

Migration of the sensor away from the point of original placement was noted in only 1 patient (due to unconsolidated host tissue) and no adverse events were recorded during the implantation procedure or thereafter. Daily dose measurements were recorded successfully for all sensors in all patients. Variance between measured and predicted dose values was reported as a frequency of error at the > or =5% and > or =8% levels. The error frequency at the > or =8% level was as high as 47%, 29%, and 21% for lung, prostate, and rectal tumors, respectively.

CONCLUSIONS

The implantable dosimeter was found to be safe and effective in measuring dose at depth. There are many factors that can influence delivered dose, and the implantable dosimeter measures the net effect of these factors. The daily sensor readings provide a new tool for rigorous treatment quality assurance.

Application of commercial MOSFET detectors for in vivo dosimetry in the therapeutic x-ray range from 80 kV to 250 kV

The purpose of this study was to investigate the dosimetric characteristics (energy dependence, linearity, fading, reproducibility, etc) of MOSFET detectors for in vivo dosimetry in the kV x-ray range. The experience of MOSFET in vivo dosimetry in a pre-clinical study using the Alderson phantom and in clinical practice is also reported. All measurements were performed with a Gulmay D3300 kV unit and TN-502RDI MOSFET detectors. For the determination of correction factors different solid phantoms and a calibrated Farmer-type chamber were used. The MOSFET signal was linear with applied dose in the range from 0.2 to 2 Gy for all energies. Due to fading it is recommended to read the MOSFET signal during the first 15 min after irradiation. For long time intervals between irradiation and readout the fading can vary largely with the detector. The temperature dependence of the detector signal was small (0.3% degrees C(-1)) in the temperature range between 22 and 40 degrees C. The variation of the measuring signal with beam incidence amounts to +/-5% and should be considered in clinical applications. Finally, for entrance dose measurements energy-dependent calibration factors, correction factors for field size and irradiated cable length were applied. The overall accuracy, for all measurements, was dominated by reproducibility as a function of applied dose. During the pre-clinical in vivo study, the agreement between MOSFET and TLD measurements was well within 3%. The results of MOSFET measurements, to determine the dosimetric characteristics as well as clinical applications, showed that MOSFET detectors are suitable for in vivo dosimetry in the kV range. However, some energy-dependent dosimetry effects need to be considered and corrected for. Due to reproducibility effects at low dose levels accurate in vivo measurements are only possible if the applied dose is equal to or larger than 2 Gy.

Energy and angular anisotropy optimisation of a p-type diode for in vivo dosimetry in photon-beam radiotherapy

We present simulation work using the Monte Carlo code MCNPX that shows that there is a possibility of improving the silicon p-type diode as a radiation dosemeter, by altering the construction of the diode. Altering the diode die thickness can reduce the inherent angular anisotropy of the diode, with little effect on its energy response. Conversely, the contact material and geometry have a large impact on the energy response with little effect on the inherent angular anisotropy. By correct choice of contact material, the typical over-response -100 keV relative to the response at 60Co energy can be reduced from approximately 20 to 4. It is expected that further enhancements may be made with different geometries and materials.

High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991

Today, conformality in radiotherapy is at the centre of many investments in equipment and staffing. To estimate the current situation within the European Organisation for Research and Treatment of Cancer (EORTC) conformal radiotherapy trial for prostate cancer, a technology questionnaire was designed to assess whether participating centres can comply with the required radiotherapy procedures of EORTC trial 22991, where a high dose is prescribed to the prostate. Questions covered various items of computed tomography, data acquisition, treatment planning, delivery and verification. All centres (n=31) replied to the questionnaire. All generate beam's eye views and dose volume histograms. All, but two, centres use digitally reconstructed radiographs to display images. The vast majority of the centres perform at least weekly treatment verification and half have access to individual in vivo dosimetry. The results of the questionnaire indicate that participating centres have access to the equipment and apply the procedures that are essential for conformal prostate radiotherapy. The technology questionnaire is the first step in the extensive quality assurance programme dedicated to this high-tech radiotherapy trial.

Quality assurance in radiotherapy: evaluation of errors and incidents recorded over a 10 year period

BACKGROUND AND PURPOSE

To establish an incident reporting system to (1) record and classify incidents, (2) assess the impact of incidents on patients in terms of dose errors, and (3) evaluate the effectiveness of the quality assurance checking program implemented at the Radiation Treatment Program at the Northeastern Ontario Regional Cancer Centre (NEORCC).

MATERIALS AND METHODS

An 'incident' is defined as an event or a series of events that has led to, or would have led to if undiscovered, dose errors to a patient undergoing radiation therapy treatment. The incidents reported between November 1992 and December 2002 were analyzed according to their source of error, stage of discovery and dose errors.

RESULTS

Between November 1992 and December 2002, 13385 patients have undergone radiation treatment at the NEORCC. Over this period of time, 624 'incidents' were reported. Source of error: the majority of the incidents (42.1%) were related to errors in 'documentation' and most of these could be attributed to 'error in data transfer' or 'inadequate communication'. 'Patient set-up error' accounted for 40.4% of the incidents and about half of these errors were related to shielding. Errors in 'treatment planning' accounted for 13.0% of the incidents. Stage of discovery: independent checks by another dosimetrist/physicist and checking during patient first set-up and port film were effective in detecting documentation errors and errors in treatment planning. The use of portal imaging (Siemens Beamview) has enabled us to detect and correct for more than 85% of reported shielding errors in patient set-up. Dose errors: 40% of the incidents were discovered before the first treatment with no dose error to patients. Overall 97.9% of the incidents had dose error of <5%.

CONCLUSIONS

Human errors occur during the various stages of the complex process of radiation therapy. If uncorrected, these could lead to substantial dose errors to patients. The implementation of a quality assurance checking program can substantially reduce these human errors but never totally eliminate them.

Feasibility study of entrance in vivo dose measurements with mailed thermoluminescence detectors

BACKGROUND AND PURPOSE

The aim of this work is to set-up mailed entrance in vivo dosimetry by means of thermoluminescence dosimeters (TLDs) in the form of LiF powder in order to assess the overall accuracy of patient treatment delivery by comparing the doses delivered to patients with the doses calculated by the treatment planning system (TPS) in different institutions.

PATIENTS AND METHODS

Two millimeter thick copper (for 6 MV photon beams) and 1.3 mm thick aluminium (for (60)Co gamma beams) build-up caps are developed. The characteristics of these build-up caps are tested by phantom measurements: the response of the TLD inside the build-up cap is compared to the ionisation chamber (IC) signal in the same irradiation conditions. A pilot study using the copper build-up cap is performed on 8 patients, treated with a 6 MV photon beam at the radiotherapy department of the University Hospital of Leuven. Additionally, a first run of mailed entrance in vivo dosimetry is performed by 18 radiotherapy centres in Europe.

RESULTS

For 80 different phantom set-ups using copper and aluminium build-up caps, the mean TLD dose compared to the IC dose is 0.993+/-0.015 (1SD). Regarding the patient measurements in the radiotherapy department of the University Hospital of Leuven, the mean ratio of the measured entrance dose (TLD) to the entrance dose calculated by the TPS, is equal to 0.986+/-0.017 (1SD) (N=8), after correction of an error detected in one of the patient treatments. For the 18 radiotherapy centres participating in the mailed in vivo TLD study, the mean measured versus stated entrance dose for patients treated in a (60)Co and 6 MV photon beam is 1.004+/-0.021 (1SD) (N=143).

CONCLUSIONS

From the results, it can be deduced that the build-up caps and the proposed calibration methodology allow the use of TLD in the form of powder to be applied in large scale in vivo dose audits.

Electron paramagnetic resonance (EPR) dosimetry using lithium formate in radiotherapy: comparison with thermoluminescence (TL) dosimetry using lithium fluoride rods

Solid-state radiation dosimetry by electron paramagnetic resonance (EPR) spectroscopy and thermoluminescence (TL) was utilized for the determination of absorbed doses in the range of 0.5-2.5 Gy. The dosimeter materials used were lithium formate and lithium fluoride (TLD-100 rods) for EPR dosimetry and TL dosimetry, respectively. 60Co gamma-rays and 4, 6, 10 and 15 MV x-rays were employed. The main objectives were to compare the variation in dosimeter reading of the respective dosimetry systems and to determine the photon energy dependence of the two dosimeter materials. The EPR dosimeter sensitivity was constant over the dose range in question, while the TL sensitivity increased by more than 5% from 0.5 to 2.5 Gy, thus displaying a supralinear dose response. The average relative standard deviation in the dosimeter reading per dose was 3.0% and 1.2% for the EPR and TL procedures, respectively. For EPR dosimeters, the relative standard deviation declined significantly from 4.3% to 1.1% over the dose range in question. The dose-to-water energy response for the megavoltage x-ray beams relative to 60Co gamma-rays was in the range of 0.990-0.979 and 0.984-0.962 for lithium formate and lithium fluoride, respectively. The results show that EPR dosimetry with lithium formate provides dose estimates with a precision comparable to that of TL dosimetry (using lithium fluoride) for doses above 2 Gy, and that lithium formate is slightly less dependent on megavoltage photon beam energy than lithium fluoride.

An implantable radiation dosimeter for use in external beam radiation therapy

An implantable radiation dosimeter for use with external beam therapy has been developed and tested both in vitro and in canines. The device uses a MOSFET dosimeter and is polled telemetrically every day during the course of therapy. The device is designed for permanent implantation and also acts as a radiographic fiducial marker. Ten dogs (companion animals) that presented with spontaneous, malignant tumors were enrolled in the study and received an implant in the tumor CTV. Three dogs received an additional implant in collateral normal tissue. Radiation therapy plans were created for the animals and they were treated with roughly 300 cGy daily fractions until completion of the prescribed cumulative dose. The primary endpoints of the study were to record any adverse events due to sensor placement and to monitor any movement away from the point of placement. No adverse events were recorded. Unacceptable device migration was experienced in two subjects and a retention mechanism was developed to prevent movement in the future. Daily dose readings were successfully acquired in all subjects. A rigorous in vitro calibration methodology has been developed to ensure that the implanted devices maintain an accuracy of +/-3.5% relative to an ionization chamber standard. The authors believe that an implantable radiation dosimeter is a practical and powerful tool that fosters individualized patient QA on a daily basis.

Comparison study of MOSFET detectors and diodes for entrancein vivodosimetry in 18 MV x-ray beams

The feasibility of dual bias dual metal oxide semiconductor field effect transistors (MOSFETs) for entrance in vivo dose measurements in high energy x-rays beams (18 MV) was investigated. A comparison with commercially available diodes for in vivo dosimetry for the same energy range was performed. As MOSFETs are sold without an integrated build-up cap, different caps were tested: 3 cm bolus, 2 cm bolus, 2 cm hemispherical cap of a water equivalent material (Plastic Water) and a metallic hemispherical cap. This metallic build-up cap is the same as the one that is mounted on the in vivo diode used in this study. Intrinsic precision and response linearity with dose were determined for MOSFETs and diodes. They were then calibrated for entrance in vivo dosimetry in an 18 MV x-ray beam. Calibration included determination of the calibration factor in standard reference conditions and of the correction factors (CF) when irradiation conditions differed from those of reference. Correction factors for field size, source surface distance, wedge, and temperature were determined. Sensitivity variation with accumulated dose and the lifetime of both types of detectors were also studied. Finally, the uncertainties of entrance in vivo measurements using MOSFET and diodes were discussed. Intrinsic precision for MOSFETs for the high sensitivity mode was 0.7% (1 s.d.) as compared to the 0.05% (1 s.d.) for the studied diodes. The linearity of the response with dose was excellent (R2 = 1.000) for both in vivo dosimetry systems. The absolute values of the studied correction factors for the MOSFETs when covered by the different build-up caps were of the same order of those determined for the diodes. However, the uncertainties of the correction factors for MOSFETs were significantly higher than for diodes. Although the intrinsic precision and the uncertainty on the CF was higher for MOSFET detectors than for the studied diodes, the total uncertainty in entrance dose determination, once they were calibrated, was of 2.9% (1 s.d.) while for diodes it was 2.0% (1 s.d.). MOSFETs showed no sensitivity variation with accumulated dose or temperature. When used in the high sensitivity mode, after approximately 50 Gy of accumulated dose MOSFETs could no longer be used as radiation dosimeters. In conclusion, MOSFETs can be used for entrance in vivo dosimetry in high energy x-rays beams if covered by an appropriate build-up cap. Metallic build-up caps, such as those used for in vivo diodes, have the advantage of greater patient comfort and less perturbation of the treatment field than the other build-up caps tested, while keeping the correction factors of the same order.

Characteristics relevant to portal dosimetry of a cooled CCD camera-based EPID

Our EPIDs have recently been equipped with Peltier-cooled CCD cameras. The CCD cooling dramatically reduced deteriorating effects of radiation damage on image quality. Over more than 600 days of clinical operation, the radiation induced noise contribution has remained stable at a very low level (1 SD < or = 0.15% of the camera dynamic range), in marked contrast with the previously used noncooled cameras. The camera response (output signal versus incident EPID radiation exposure) can be accurately described with a quadratic function. This response reproduced well, both in short and long term (variation < 0.2% respectively < 0.4% (1 SD)), rendering the cooled camera well-suited for EPID dosimetry applications.

Entrance dose measurement: a simple and reliable technique

Verification of tumor dose for patients undergoing external beam radiotherapy is an important part of quality assurance programs in radiation oncology. Among the various methods available, entrance dose in vivo is one reliable method used to verify the tumor dose delivered to a patient. In this work, entrance dose measurements using LiF:Mg;Ti and LiF:Mg;Cu;P thermoluminescent dosimeters (TLDs) without buildup cap was carried out. The TLDs were calibrated at the surface of a water equivalent phantom against the maximum dose, using 6- and 10-MV photon and 9-MeV electron beams. The calibration geometry was such that the TLDs were placed on the surface of the "solid-water" phantom and a calibrated ionization chamber was positioned inside the phantom at calibration depth. The calibrated TLDs were then utilized to measure the entrance dose during the treatment of actual patients. Measurements were also carried out in the same phantom simultaneously to check the stability of the system. The dose measured in the phantom using the TLDs calibrated for entrance dose to 6-and 10-MV photon beams was found to be close to the dose determined by the treatment planning system (TPS) with discrepancies of not more than 4.1% (mean 1.3%). Consequently, the measured entrance dose during dose delivery to the actual patients with a prescribed geometry was found to be compatible with a maximum discrepancy of 5.7% (mean 2.2%) when comparison was made with the dose determined by the TPS. Likewise, the measured entrance dose for electron beams in the phantom and in actual patients using the calibrated TLDs were also found to be close, with maximum discrepancies of 3.2% (mean 2.0%) and 4.8% (mean 2.3%), respectively. Careful implementation of this technique provides vital information with an ability to confidently accept treatment algorithms derived by the TPS or to re-evaluate the parameters when necessary.

Electron dose calculations: a comparison of two commercial treatment planning computers

The accuracy of electron dose calculations performed by two commercially available treatment planning systems, Varian Cadplan and MDS Nordion Helax-TMS, were assessed. Three tests designed to reproduce clinical treatments likely to result in dose nonuniformity have been carried out. The tests examined oblique incidence of the electron beam; incidence on a surface containing a step shape; and incidence on a phantom containing a small air cavity. Dose calculations performed by the planning systems were compared with thermoluminescence dosimetry (TLD) measurements in a WTe electron solid water phantom. A Varian 2100C linear accelerator was used. In most situations, the discrepancy between calculated and measured dose was within the tolerance specified by the ICRU; however, some exceptions were noted. Helax-TMS produced errors of 5 mm in the position of the 10% isodose line in the penumbra of the obliquely incident beam. Both Cadplan and Helax-TMS overestimated the surface dose adjacent to a step in the beam entry surface by approximately 15%. An overestimation of 10% in dose was calculated by both systems downstream of the small air cavity. Discrepancies between the measured and calculated monitor units lay within the uncertainty limits of the measurements. In conclusion, calculations of absorbed dose from electron beams performed by Varian Cadplan and MDS Nordion Helax-TMS result in significant errors at shallow depths near surface irregularities and downstream of small air cavities.

In vivo dosimetry using radiochromic films during intraoperative electron beam radiation therapy in early-stage breast cancer

BACKGROUND AND PURPOSE

To check the dose delivered to patients during intraoperative electron beam radiation therapy (IOERT) for early breast cancer and also to define appropriate action levels.

PATIENTS AND METHODS

Between December 2000 and June 2001, 54 patients affected by early-stage breast cancer underwent exclusive IOERT to the tumour bed using a Novac7 mobile linac, after quadrantectomy. Electron beams (5, 7, 9 MeV) at high dose per pulse values (0.02-0.09 Gy/pulse) were used. The prescribed single dose was 21 Gy at the depth of 90% isodose (14-22 mm). In 35 cases, in vivo dosimetry was performed. The entrance dose was derived from the surface dose measured with thin and calibrated MD-55-2 radiochromic films, wrapped in sterile envelopes. Films were analysed 24-72 h after the irradiation using a charge-coupled-device imaging system. Field disturbance caused by the film envelope was negligible.

RESULTS

The mean deviation between measured and expected doses was 1.8%, with one SD equal to 4.7%. Deviations larger than 7% were found in 23% of cases, never consecutively, not correlated with beam energy or field size and with no evidence of linac daily output variation or serious malfunctioning or human mistake. The estimated overall uncertainty of dose measurement was about 4%. In vivo dosimetry appeared both reliable and feasible. Two action levels, for unexplained observed deviations larger than 7 and 10%, were preliminary defined.

CONCLUSIONS

Satisfactory agreement between measured and expected doses was found. The implementation of in vivo dosimetry in IOERT is suggested, particularly for patients enrolled in a clinical trial.

Feasible measurement errors when undertaking in vivo dosimetry during external beam radiotherapy of the breast

In vivo dosimetry is a proven reliable method of checking overall treatment accuracy, allowing verification of dosimetry and dose calculation as well as patient treatment setup. We conducted a pilot study to assess the clinical utility of in vivo dosimetry in our department. Diodes (calibrated for typical treatment conditions) were used to record entrance dose measurements on 62 patients representing a variety of treatment sites. Measurements were compared with predictions from the planning system, with results found to be in tolerance for the majority of treatment sites. However, large discrepancies were encountered for measurements performed during breast irradiation (up to 16% for lateral tangential fields). The sensitivity of the recorded entrance dose to the positioning error of the diode placement was examined. The sensitivity of diode signal to small changes in position were compared with feasible variations in other parameters (e.g., dosimetry, FSD at setup). For the breast irradiation technique considered, wedges are used for the majority of fields. It was found that a proportion of error was predominantly due to the use of wedges and the presence of significantly nonuniform patient contours. In combination with diode placement errors, this resulted in increased measurement error. Correct diode placement is critical to ensure accurate data collection. The results of this study indicate the importance of separating errors due to measurement technique from actual treatment/setup errors.

In vivo alanine/EPR dosimetry in daily clinical practice: a feasibility study

PURPOSE

The objective of this study was evaluation of accuracy of in vivo dosimetry using electron paramagnetic resonance (EPR) in alanine. Additionally, we aimed to identify sources of uncertainty in dose determination and quantitative assessment of physical factors that may result in discrepancies between the measured and planned single-fraction doses.

METHODS AND MATERIALS

The measurements were performed using detectors in a form of 1.6 cm x 1.6 cm polyethylene sachets filled with powdered L-alanine. The detectors were taped to the patient's skin and measured the entrance doses for (60)Co and electron beams. Some detectors were covered with buildup material, and some measured the "skin dose." The EPR measurements were performed with a Varian E-4 spectrometer.

RESULTS

The calculated uncertainty of EPR measured doses was dependent on measured doses and varied from 6.6% for 0.5 Gy to 3.2% for 2 Gy. The calculated uncertainty was in concordance with experimentally determined reproducibility of EPR signals. However, the deviations between measured and planned doses exceeded the uncertainty range of EPR measurements, which can be attributed to uncertainty in determination of actually delivered doses to the detectors, on the basis of treatment planning data.

CONCLUSION

The accuracy of dose determination by EPR measurements was shown to be achievable within the 5% limit recommended by the ICRU for doses above 0.7 Gy. The accuracy of in vivo verification of radiotherapy doses by in vivo EPR dosimetry can be improved by meticulous selection of measurement conditions, i.e., radiation fields and detector positions, ensuring accurate calculation of doses delivered to the dosimeters.

Characterization of an in vivo diode dosimetry system for clinical use

An in vivo dosimetry system that uses p-type semiconductor diodes with buildup caps was characterized for clinical use on accelerators ranging in energy from 4 to 18 MV. The dose per pulse dependence was investigated. This was done by altering the source-surface distance, field size, and wedge for photons. The off-axis correction and effect of changing repetition rate were also investigated. A model was developed to fit the measured two-dimensional diode correction factors.

Thin sintered Al2O3 pellets as thermoluminescent dosimeters for the therapeutic dose range

Thermoluminescent properties of sintered alumina pellets were investigated with the aim of using them as radiation dosimeters. Peak temperatures, signal reproducibility, fading, curves of the response to X-radiation, as well as energy and angular dependences were studied. The results show that the pellets can be used in quality control programs in the therapeutic dose range.

Dosimetric considerations for patients with HIP prostheses undergoing pelvic irradiation. Report of the AAPM Radiation Therapy Committee Task Group 63

This document is the report of a task group of the Radiation Therapy Committee of the AAPM and has been prepared primarily to advise hospital physicists involved in external beam treatment of patients with pelvic malignancies who have high atomic number (Z) hip prostheses. The purpose of the report is to make the radiation oncology community aware of the problems arising from the presence of these devices in the radiation beam, to quantify the dose perturbations they cause, and, finally, to provide recommendations for treatment planning and delivery. Some of the data and recommendations are also applicable to patients having implanted high-Z prosthetic devices such as pins, humeral head replacements. The scientific understanding and methodology of clinical dosimetry for these situations is still incomplete. This report is intended to reflect the current state of scientific understanding and technical methodology in clinical dosimetry for radiation oncology patients with high-Z hip prostheses.

Portal dose image verification: formalism and application of the collapsed cone superposition method

A formalism tailored for portal dose image verification is proposed to facilitate the comparison of calculated and measured portal dose distributions. Each portal image is converted into a dose proportional image and normalized to the reference beam calibration dose per monitor unit. The calculated or measured dose to a detector phantom is accordingly normalized so as to enable direct comparison. The collapsed cone kernel superposition method is adapted and evaluated for calculation of portal dose distributions in a water-equivalent detector phantom through comparisons with Monte Carlo calculations and with measurements. The deviation compared with Monte Carlo calculations for 6 and 15 MV was between +0.9% (the 0.9 quantile) and -2.1% (the 0.1 quantile) for a range of investigated geometries. Collapsed cone calculations compared with measurements for clinical fields agreed within [-1.9%, +2.4%] for 15 MV and [-0.9%, +3.2%] for 6 MV for the 0.1 and 0.9 quantiles, respectively. Hence, the absolute portal dose to a detector phantom could be calculated and verified well within the present accuracy requirements for clinical dose calculations.

In vivo estimation of midline dose maps by transit dosimetry in head and neck radiotherapy

The aim of the present study is to compare the calculated midline dose map with the in vivo measured midline dose map, using portal detectors in conjunction with a pair of diodes. Measurements were performed in 10 patients treated for head/neck cancer and irradiated with lateral opposed 6 MV X-ray beams. The relative exit dose map, derived from transmission dose data of a portal film combined with the absolute entrance/exit dose measured by the diodes, can be used to derive the corresponding midline dose map by applying appropriate algorithms. Midplane dose values were estimated in eight relevant anatomic positions and compared with the corresponding calculated values with our three-dimensional (3D) treatment planning system using two-dimensional (2D) (Batho) and 3D (ETAR) inhomogeneity correction algorithms. In vivo estimated midplane doses agree within +/-3.5% relative to treatment planning calculations in 89 of 116 measurements points, with only 4 of 116 points outside +/-5%. A variation between measured and calculated dose can be found according to anatomical location. For air inhomogeneity, mean deviations were +2.2% (1 standard deviation (SD) approximately 1.7%) for both Batho and ETAR algorithms; for bone structures, mean deviations were approximately -0.6% (1 SD approximately 2.7%) for both algorithms. The worst agreement was found in the anterior neck where the mean deviation between measured and calculated midline dose was +3.1% (1 SD=1.4%) and +3.4% (1 SD= 2%) using Batho and ETAR, respectively. Sufficiently accurate 2D midplane dose maps may be simply obtained in vivo in the irradiation of head/neck cancer by using a portal detector in combination with a pair of diodes, in order to verify the dose actually delivered during treatment.

An investigation of a new amorphous silicon electronic portal imaging device for transit dosimetry

The relationship between the pixel value and exit dose was investigated for a new commercially available amorphous silicon electronic portal imaging device. The pixel to dose mapping function was established to be linear for detector distances between 116.5 cm to 150 cm from the source, radiation field sizes from 5 x 5 cm2 to 20 x 20 cm2 and beam energies of 6 to 18 MV. Coefficients in the mapping function were found to be dependent on beam energy and field size. Open and wedged field profiles measured with the device showed agreement to a maximum of 5% and 8%, respectively, as compared to film. A comparison of relative transmission measurements between the EPID and ion chamber indicate a maximum deviation of 6% and 2% at 6 and 18 MV, respectively, for an attenuator thickness of 21 cm and SDD > or = 130 cm. It was found that accuracies of better than 1% could be obtained if detector position and field size specific fitting parameters were used to generate unique mapping functions for each configuration.

A simplified approach for exit dose in vivo measurements in radiotherapy and its clinical application

This is a study using LiF:Mg;Ti thermoluminescent dosimeter (TLD) rods in phantoms to investigate the effect of lack of backscatter on exit dose. Comparing the measured dose with anticipated dose calculated using tissue maximum ratio (TMR) or percentage depth dose (PDD) gives rise to a correction factor. This correction factor may be applied to in-vivo dosimetry results to derive true dose to a point within the patient. Measurements in a specially designed humanoid breast phantom as well as patients undergoing radiotherapy treatment were also been done. TLDs with reproducibility of within +/- 3% (1 SD) are irradiated in a series of measurements for 6 and 10 MV photon beams from a medical linear accelerator. The measured exit doses for the different phantom thickness for 6 MV beams are found to be lowered by 10.9 to 14.0% compared to the dose derived from theoretical estimation (normalized dose at dmax). The same measurements for 10 MV beams are lowered by 9.0 to 13.5%. The variations of measured exit dose for different field sizes are found to be within 2.5%. The exit doses with added backscatter material from 2 mm up to 15 cm, shows gradual increase and the saturated values agreed within 1.5% with the expected results for both beams. The measured exit doses in humanoid breast phantom as well as in the clinical trial on patients undergoing radiotherapy also agreed with the predicted results based on phantom measurements. The authors' viewpoint is that this technique provides sufficient information to design exit surface bolus to restore build down effect in cases where part of the exit surface is being considered as a target volume. It indicates that the technique could be translated for in vivo dose measurements, which may be a conspicuous step of quality assurance in clinical practice.

IMRT verification by three-dimensional dose reconstruction from portal beam measurements

A method of reconstructing three-dimensional, in vivo dose distributions delivered by intensity-modulated radiotherapy (IMRT) is presented. A proof-of-principle experiment is described where an inverse-planned IMRT treatment is delivered to an anthropomorphic phantom. The exact position of the phantom at the time of treatment is measured by acquiring megavoltage CT data with the treatment beam and a research prototype, flat-panel, electronic portal imaging device. Immediately following CT imaging, the planned IMRT beams are delivered using the multiple-static field technique. The delivered fluence is sampled using the same detector as for the CT data. The signal measured by the portal imaging device is converted to primary fluence using an iterative phantom-scatter estimation technique. This primary fluence is back-projected through the previously acquired megavoltage CT model of the phantom, with inverse attenuation correction, to yield an input fluence map. The input fluence maps are used to calculate a "reconstructed" dose distribution using the same convolution/superposition algorithm as for the original planning dose calculation. Both relative and absolute dose reconstructions are shown. For the relative measurements, individual beam weights are taken from measurements but the total dose is normalized at the reference point. The absolute dose reconstructions do not use any dosimetric information from the original plan. Planned and reconstructed dose distributions are compared, with the reconstructed relative dose distribution also being compared to film measurements.

Verification of the dose to the isocentre in stereotactic plans

BACKGROUND AND PURPOSE

The aim of the study was: (a) to develop a simple, reproducible, technique to verify the dose to the isocentre, in a typical stereotactic treatment plan, for collimators from 12.5 to 40 mm in diameter; (b) to investigate a variety of detectors to compare different approaches; and (c) to introduce the technique into a quality assurance programme.

MATERIAL AND METHODS

The symmetry, directional response and stability of calibration of a small 0.125 cm(3) ion chamber, a diamond and three types of diode (photon, electron and stereotactic) were tested. Correction factors were calculated to account for directional dependence, where appropriate and calibration factors were obtained to convert each reading to absorbed dose in water. Single arcs and typical four arc treatments were planned on XKnife and the dose to the isocentre verified in phantom with each usable detector.

RESULTS

The ion chamber showed no asymmetry, the stereotactic diodes exhibited 4% and the others 1-2%. Maximum directional dependence was 1% for the ion chamber and diamond and 7-20% for the diodes. Correction factors were calculated to account for this. Only the response of the diodes decreased with cumulative dose; the response of the other detectors remained constant. The ion chamber, electron diode and diamond measured the dose in single arcs to within 1.5% of calculation, in the 40 and 12.5 mm collimators. The photon diode was within 3.5 and 2.5% in the largest and smallest collimators, respectively.

CONCLUSION

A simple method of verification was developed. The ion chamber, the diamond and the electron diode were found to be the best detectors to verify the dose to the isocentre in a typical multiple arc treatment for collimators between 40 and 12.5 mm in diameter. The technique has been incorporated into a quality assurance programme, using the ion chamber and diamond, on a twice yearly basis.

Dosimetric validation for multileaf collimator-based intensity-modulated radiotherapy: a review

The creation of intricate dose distributions produced by intensity-modulated radiotherapy (IMRT) depends on complex planning systems and specialized mechanical devices. The many possible sources of inaccuracy and the complexity of the dose maps themselves require that a substantial effort be made to ensure that calculated and delivered dose distributions agree. This review provides an overview of the current status of the validation of dose predictions of IMRT planning systems by comparisons with measurements. Emphasis is placed on multileaf collimator- (MLC) based IMRT. Discrepancies between calculations and measurements may be due to any of 3 causes: errors and uncertainties in the dose calculation algorithm, in measurements, or in beam delivery by the accelerator/MLC combination. Some of the factors affecting dosimetry include: the technique employed for modulating the fluence, the dose calculation algorithm and other aspects of the planning system, mechanical limitations of the MLC hardware, dosimetric characteristics of the MLC, such as MLC leakage and rounded leaf ends, the choice of dosimeter, and the measurement geometry and technique. The advantages and drawbacks of various dosimeters including film, ion chambers, thermoluminescent dosimetry, and electronic portal imaging devices are discussed. The steps involved in validating dosimetrically a planning system are outlined, including the various fields that need to be measured, the phantoms that may be used, and measurement techniques. The achievable accuracy of dosimetry for IMRT is discussed.

Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation

PURPOSE

To assess the impact of lung dose on lethal pulmonary complications (LPCs) in a single-center group of patients with hematologic malignancies treated with total body irradiation (TBI) in the conditioning regimen for bone marrow transplantation (BMT).

METHODS

The mean lung dose of 101 TBI-conditioned patients was assessed by a thorough (1 SD around 2%) in vivo transit dosimetry technique. Fractionated TBI (10 Gy, 3.33 Gy/fraction, 1 fraction/d, 0.055 Gy/min) was delivered using a lateral-opposed beam technique with shielding of the lung by the arms. The median lung dose was 9.4 Gy (1 SD 0.8 Gy, range 7.8--11.4). The LPCs included idiopathic interstitial pneumonia (IIP) and non-idiopathic IP (non-IIP).

RESULTS

Nine LPCs were observed. LPCs were observed in 2 (3.8%) of 52 patients in the group with a lung dose < or = 9.4 Gy and in 7 (14.3%) of 49 patients in the >9.4 Gy group. The 6-month LPC risk was 3.8% and 19.2% (p = 0.05), respectively. A multivariate analysis adjusted by the following variables: type of malignancy (acute leukemia, chronic leukemia, lymphoma, myeloma), type of BMT (allogeneic, autologous), cytomegalovirus infection, graft vs. host disease, and previously administered drugs (bleomycin, cytarabine, cyclophosphamide, nitrosoureas), revealed a significant and independent association between lung dose and LPC risk (p = 0.02; relative risk = 6.7). Of the variables analyzed, BMT type (p = 0.04; relative risk = 6.6) had a risk predictive role.

CONCLUSION

The mean lung dose is an independent predictor of LPC risk in patients treated with the 3 x 3.33-Gy low-dose-rate TBI technique. Allogeneic BMT is associated with a higher risk of LPCs.

A linear diode array (JFD-5) for match line in vivo dosimetry in photon and electron beams; evaluation for a chest wall irradiation technique

BACKGROUND AND PURPOSE

In vivo dosimetry using thermoluminiscence detectors (TLD) is routinely performed in our institution to determine dose inhomogeneities in the match line region during chest wall irradiation. However, TLDs have some drawbacks: online in vivo dosimetry cannot be performed; generally, doses delivered by the contributing fields are not measured separately; measurement analysis is time consuming. To overcome these problems, the Joined Field Detector (JFD-5), a detector for match line in vivo dosimetry based on diodes, has been developed. This detector and its characteristics are presented.

MATERIALS AND METHODS

The JFD-5 is a linear array of 5 p-type diodes. The middle three diodes, used to measure the dose in the match line region, are positioned at 5-mm intervals. The outer two diodes, positioned at 3-cm distance from the central diode, are used to measure the dose in the two contributing fields. For three JFD-5 detectors, calibration factors for different energies, and sensitivity correction factors for non-standard field sizes, patient skin temperature, and oblique incidence have been determined. The accuracy of penumbra and match line dose measurements has been determined in phantom studies and in vivo.

RESULTS

Calibration factors differ significantly between diodes and between photon and electron beams. However, conversion factors between energies can be applied. The correction factor for temperature is 0.35%/ degrees C, and for oblique incidence 2% at maximum. The penumbra measured with the JFD-5 agrees well with film and linear diode array measurements. JFD-5 in vivo match line dosimetry reproducibility was 2.0% (1 SD) while the agreement with TLD was 0.999+/-0.023 (1 SD).

CONCLUSION

The JFD-5 can be used for accurate, reproducible, and fast on-line match line in vivo dosimetry.

On the verification of the incident energy fluence in tomotherapy IMRT

For any radiotherapy verification technique, it is desirable that issues with the accelerator, multileaf collimator and patient position be detected. In previous works, an effective method for this level of verification was presented. This paper identifies second-order issues affecting the part of the process in which the incident energy fluence is verified. These problems will affect any rotational intensity-modulated radiotherapy delivery that divides each rotation or arc into projections: however the solutions offered in this paper are specific to the method previously developed. The issues affecting the energy fluence verification method include leaf bouncing. delivery implementation and leaf latency. All three matters were found to introduce small errors in the verified energy fluence values for a small fraction of leaf states. The overall effect on the deposited dose over the course of a rotational delivery involving thousands of beam pulses per rotation is negligible. Regardless, effective correction strategies are presented; these are utilized in order to characterize both the delivered energy fluence and deposited dose as accurately as possible.

In vivo dosimetry using a single diode for megavoltage photon beam radiotherapy: implementation and response characterization

The AAPM Task Group 40 reported that in vivo dosimetry can be used to identify major deviations in treatment delivery in radiation therapy. In this paper, we investigate the feasibility of using one single diode to perform in vivo dosimetry in the entire radiotherapeutic energy range regardless of its intrinsic buildup material. The only requirement on diode selection would be to choose a diode with the adequate build up to measure the highest beam energy. We have tested the new diodes from Sun Nuclear Corporation (called QED and ISORAD-p--both p-type) for low-, intermediate-, and high-energy range. We have clinically used both diode types to monitor entrance doses. In general, we found that the dose readings from the ISORAD (p-type) are closer of the dose expected than QED diodes in the clinical setting. In this paper we report on the response of these newly available ISORAD (p-type) diode detectors with respect to certain radiation field parameters such as source-to-surface distance, field size, wedge beam modifiers, as well as other parameters that affect detector characteristics (temperature and detector-beam orientation). We have characterized the response of the high-energy ISORAD (p-type) diode in the low- (1-4 MV), intermediate- (6-12 MV), and high-energy (15-25 MV) range. Our results showed that the total variation of the response of high-energy ISORAD (p-type) diodes to all the above parameters are within +/-5% in most encountered clinical patient treatment setups in the megavoltage photon beam radiotherapy. The usage of the high-energy buildup diode has the additional benefit of amplifying the response of the diode reading in case the wrong energy is used for patient treatment. In the light of these findings, we have since then switched to using only one single diode type, namely the "red" diode; manufacturer designation of the ISORAD (p-type) high-energy (15-25 MV) range diode, for all energies in our institution and satellites.

Phantom dosimetry for conformal stereotactic radiotherapy with a head and neck localizer frame

Linear accelerator based stereotactic radiotherapy (SRT) with the Gill-Thomas-Cosman (GTC) re-locatable frame has been in use for several years. The use of the frame is limited to treating lesions above the hard palate. For treating tumours in the head and neck region, the Head and Neck Localizer (HNL) frame has been designed by Radionics Inc. for use with their XPlan treatment planning software. In this study we have used a spherical acrylic phantom commercially known as the 'Lucy' phantom (Sandstrom Sandstrom Trade and Technology Inc.) to perform thermoluminiscent as well as film dosimetry for the HNL frame. A radio-opaque marker was placed in the phantom and a film test carried out to verify the accuracy in isocentre positioning. The results of the dosimetry with TLD were within 2% for points near the isocentre and 5% (or 2 mm in steep gradients) in the planning target volume (PTV). In regions of low dose, larger percentage differences in local dose were observed, but all differences were within 5% of isocentre dose. The film dosimetry provided dose distributions that matched well with those generated by the XPlan stereotactic treatment planning software.

Analytical calculation of the portal scatter to primary dose ratio: an EGS4 Monte Carlo and experimental validation at large air gaps

An analytical approximation for the scatter to primary dose ratio (SPR) on the central axis was validated against Monte Carlo results and experimental measurements for homogeneous and inhomogeneous phantoms. The analytical approximation only included first-order Compton scatter. The contribution to the total SPR from first-order Compton scatter, multiply scattered photons and electron scatter was investigated using Monte Carlo simulation for homogeneous phantoms (up to 30 cm thick for 6 and 18 MV beams; source to detector distances from 150 to 230 cm) as well as for a neck, thorax and pelvis phantom. SPRs were measured on the central axis with an ionization chamber for water phantoms (up to 20 cm thick at 4 MV, 30 cm for 6 MV and 10 MV and 40 cm for 18 MV; source to detector distances of 185 and 200 cm) and for phantoms representing the neck, thorax and pelvis (for air gaps of 50 cm and larger). The mean difference between the experimental and analytical SPRs on the central axis for source to detector distances of 170 cm or greater was within: -0.003 (neck); -0.012 (thorax); -0.028 (pelvis, 10 MV) and 0.008 (pelvis, 18 MV) respectively.

The thermal characteristics of different diodes on in vivo patient dosimetry

Diode sensitivity variations with temperature (SVWT) have been reported to vary from small negative values up to 0.6% per degrees C. Thus it is possible for diode calibration factors established at room temperature (approximately 20 degrees C) to yield errors in the range of -1% to +9% when diodes are placed on a patient's skin (approximately 30 degrees C) for in vivo entrance dose measurements. In this study we simulated several skin temperatures using a temperature-controlled aluminum surface in contact with a section of Bolus. The internal temperatures of several diodes with different buildup thickness were monitored as a function of time when placed in contact with the heated bolus. Our results indicate that for different combinations of room temperature (18 degrees C-23 degrees C) and patient skin temperature (28 degrees C-34 degrees C) diodes reached 90% of their equilibrium temperature within 3-5 min. In addition, the range of typical skin temperatures was determined by measurements performed on a number of actual patients under clinical conditions. Based on the results of our experiments a protocol was developed to minimize the temperature based errors for in vivo dosimetry.

Clinical implementation of dynamic multileaf collimation for compensated bladder treatments

BACKGROUND AND PURPOSE

To describe the clinical implementation of dynamic multileaf collimation (DMLC). Custom compensated four-field treatments of carcinoma of the bladder have been used as a simple test site for the introduction of intensity modulated radiotherapy.

MATERIALS AND METHODS

Compensating intensity modulations are calculated from computed tomography (CT) data, accounting for scattered, as well as primary radiation. Modulations are converted to multileaf collimator (MLC) leaf and jaw settings for dynamic delivery on a linear accelerator. A full dose calculation is carried out, accounting for dynamic leaf and jaw motion and transmission through these components. Before treatment, a test run of the delivery is performed and an absolute dose measurement made in a water or solid water phantom. Treatments are verified by in vivo diode measurements and real-time electronic portal imaging.

RESULTS

Seven patients have been treated using DMLC. The technique improves dose homogeneity within the target volume, reducing high dose areas and compensating for loss of scatter at the beam edge. A typical total treatment time is 20 min.

CONCLUSIONS

Compensated bladder treatments have proven an effective test site for DMLC in an extremely busy clinic.

A simple and robust method for in vivo midline dose map estimations using diodes and portal detectors

INTRODUCTION

This work investigates the possibility of using a pair of diodes on the beam axis in conjunction with a portal imaging detector to estimate in vivo midline dose distributions, without any additional patient information, related to the external body contour.

MATERIALS AND METHODS

In the proposed method, the patient is considered equivalent to a parallelepiped phantom with a thickness z equal to the patient's physical thickness on the field axis with a variable electronic density rho, depending on the water-equivalent thickness. Based on this assumption, if the air gap between portal detector and patient is kept small (within 10-15 cm), the relative exit dose map may be assumed to be equal to the corresponding map measured at the portal detector level by geometrical back projection to the corresponding exit points. The relative exit dose map is then normalized at the on-axis value measured by the exit diode. The entrance dose map is derived by correcting the absolute dose value measured with the diode at the entrance surface by the off-axis ratios. For each pair of entrance and exit doses, the midline dose may be estimated by applying algorithms reported in literature. The method was tested in 6 MV beams using portal film as detector and the Huyskens and Rizzotti algorithms for midline dose estimation. Tests on homogeneous cubic phantoms, homogeneous phantoms with varying thickness symmetrically (simulating head and neck regions) and asymmetrically (simulating abdomen/pelvis region), and a half-sphere phantom with simulating the breast, were performed. Midline doses estimated with the proposed method have been compared with corresponding ones measured by ionisation chamber.

RESULTS AND DISCUSSION

Results confirm that the proposed method can be used to estimate midplane dose maps within 2-3% for most clinically suitable situations. For homogeneous symmetrical phantoms the agreement between estimated and measured midline doses decreases with the phantom-portal film distance, the field sizes and the thickness. For homogeneous asymmetrical phantoms the percentage deviations are generally within 3%. Discrepancies larger than 3% (up to 5-6%) are found only for "stressed" irradiation geometries which are not linked with any clinical condition.

CONCLUSIONS

The obtained results not only show the accuracy of the proposed method but, due to its simplicity, suggest a rapid clinical implementation of this method in relevant clinical situations such as head-neck, breast and abdomen/pelvis irradiation. Previous investigations which confirmed the possibility of using portal detectors for transit dosimetry in inhomogeneous regions suggest the further exploration of the accuracy and the limits of the proposed method in such cases.

Chest wall irradiation with MLC-shaped photon and electron fields

PURPOSE

To improve the treatment technique for chest wall irradiation, using the multileaf collimator (MLC) of the MM50 Racetrack Microtron to shape both photon and electron beams, and to check the dose delivery in the match-line region of these fields for the routine and improved technique.

METHODS AND MATERIALS

Using diode and film phantom measurements, the optimal number of photon beam segments and their positions relative to the electron beam were determined. On phantoms, and during actual patient treatment using in vivo dosimetry, the dose homogeneity in the match-line region was determined for both the routine and improved techniques.

RESULTS

Three photon beam segments (9-mm gap, perfect match, and 9-mm overlap) were used to match the electron beam, resulting in minimum-maximum dose values in the match-line region of 88-109%, compared to 80-115% for the routine technique (2 photon beam segments). During patient treatment, the average minimum and maximum dose values were 95% and 115%, respectively, compared to 78% and 127%, respectively, for the routine technique. The interfraction variation in dose delivery was reduced from 11.0% (1 SD) to 4.6% (1 SD). The actual treatment time was reduced from 10 to 4.5 min.

CONCLUSION

Using the MLC of the MM50 to shape both photon and electron beams, an improved treatment technique for chest wall irradiation was developed, which is less labor intensive, faster, and yields a more homogeneous, and better reproducible dose delivery.

Clinical experience with routine diode dosimetry for electron beam radiotherapy

PURPOSE

Electron beam radiotherapy is frequently administered based on clinical setups without formal treatment planning. We felt, therefore, that it was important to monitor electron beam treatments by in vivo dosimetry to prevent errors in treatment delivery. In this study, we present our clinical experience with patient dose verification using electron diodes and quantitatively assess the dose perturbations caused by the diodes during electron beam radiotherapy.

METHODS AND MATERIALS

A commercial diode dosimeter was used for the in vivo dose measurements. During patient dosimetry, the patients were set up as usual by the therapists. Before treatment, a diode was placed on the patient's skin surface and secured with hypoallergenic tape. The patient was then treated and the diode response registered and stored in the patient radiotherapy system database via our in-house software. A customized patient in vivo dosimetry report showing patient details, expected and measured dose, and percent difference was then generated and printed for analysis and record keeping. We studied the perturbation of electron beams by diodes using film dosimetry. Beam profiles at the 90% prescription isodose depths were obtained with and without the diode on the beam central axis, for 6-20 MeV electron beams and applicator/insert sizes ranging from a 3-cm diameter circular field to a 25 x 25 cm open field.

RESULTS

In vivo dose measurements on 360 patients resulted in the following ranges of deviations from the expected dose at the various anatomic sites: Breast (222 patients) -20.3 to +23.5% (median deviation 0%); Head and Neck (63 patients) -21.5 to +14.8% (median -0.7%); Other sites (75 patients) -17.6 to +18.8% (median +0.5%). Routine diode dosimetry during the first treatment on 360 patients (460 treatment sites) resulted in 11.5% of the measurements outside our acceptable +/-6% dose deviation window. Only 3.7% of the total measurements were outside +/-10% dose deviation. Detailed investigations revealed that the dose discrepancies, overwhelmingly, were due to inaccurate diode orientation and positioning, especially in the regions with rapidly changing contours and/or sloping surfaces. The presence of a diode in the treatment field was found, in some cases, to cause significant dose reduction, most noticeable with smaller fields and lower energy beams. The reduction in dose ranged from 16% (for a 6 MeV beam and a 3 cm diameter circular field) to 4% (for a 12 MeV beam and a 10 x 10 cm field).

CONCLUSIONS

Diode dosimetry was found to be convenient and valuable for verifying in real time the dose delivery accuracy of electron beam treatments, but with some caveats. When treating a small field by low energy electrons, frequent use of diodes is undesirable, because it might result in appreciable reduction of dose to the target volume.

Independent corroboration of monitor unit calculations performed by a 3D computerized planning system

The checking of monitor unit calculations is recognized as a vital component of quality assurance in radiotherapy. Using straightforward but detailed computer-based verification calculations it is possible to achieve a precision of 1% when compared with a three-dimensional (3D) treatment planning system monitor unit calculation. The method is sufficiently sensitive to identify significant errors and is consistent with current recommendations on the magnitude of uncertainties in clinical dosimetry. Moreover, the approach is accurate in the sense of being highly consistent with the validated 3D treatment planning system's calculations.

Quality assurance by systematic in vivo dosimetry: results on a large cohort of patients

BACKGROUND

In vivo dosimetry is widely considered to be an important tool for quality assurance in external radiotherapy.

INTRODUCTION

In this study we report on our experience over more than 4 years in systematic in vivo dosimetry with diodes.

MATERIALS AND METHODS

From November '94 an in vivo entrance dosimetry check was performed for every new patient irradiated at one of our treatment units (Linac 6/100, 6 MV X-rays). Diodes were calibrated in terms of entrance dose; appropriate correction factors had been previously assessed (taking SSDs, field width, wedge, oblique incidence and blocking tray into account) and were individually applied to in vivo diode readings. The in vivo measured entrance dose was compared with the expected one, with a 5% action level; if a larger deviation was found, all treatment parameters were verified, and the in vivo dosimetry check was repeated. During the period November '94-May '99, 2824 measurements on 1433 patients were collected.

RESULTS

Nine out of 1433 (0.63%) serious systematic errors (leading to a 5% or more on the delivered dose to the PTV) were detected by in vivo dosimetry; four out of nine would produce a 10% or more error if not detected. The rate of serious systematic errors detected by an independent check of treatment chart and MU calculation was found to be 1.5%, showing that less than 1/3 of the errors escapes this check. One hundred and twelve out of 1433 (7.8%) patients had more than one check: the rate of second checks was significantly higher for breast patients (31/250, 12.4%) against non-breast patients (81/1183, 6.8%, P=0.003). A number of patients demonstrated a persistent relatively large error even after two or more checks. For almost all patients the cause of the deviation was assessed; the most frequent cause was the difficulty in correctly positioning the patient and/or the diode. When analyzing the distribution of the deviations between measured and expected entrance doses (excluding first checks in the case of repetition of the in vivo dosimetry control) the mean deviation was 0.4% with a standard deviation equal to 3.0%. The rates of deviations larger than 5 and 7% were 9.9 and 2.6%, respectively. When considering the same data taking the average deviation in the case of opposed beams, the SD became 2.6% and the rates of deviations larger than 5 and 7%, respectively, 5.2 and 0.8%. When dividing the beams according to their orientation, significantly higher rates of large deviations (>5 and 7%) were found for oblique and posterior-anterior (PA) fields against lateral and anterior-posterior (AP) fields (P<0.05). Similarly, higher rates of large deviations were found for wedged fields against unwedged fields (P<0.03) and for blocked fields against unblocked fields (P<0.01). When dividing the data according to the anatomical district, accuracy was worse for breast (mean deviation 0.1%, 1 SD: 3.5%) and neck AP-PA fields (mean deviation 1%, 1 SD: 3,4%). Better accuracy was found for vertebrae (0.1%, 1 SD 2. 1%) and brain patients (-0.7%, 1 SD: 2.6%). During the considered period, in vivo dosimetry was also able to promptly detect a systematic error caused by a wrong resetting of the simulator height couch indicator, with a consequent error in the estimate of patient thickness of about 4 cm.

CONCLUSIONS

In our experience, systematic in vivo dosimetry demonstrated to be a valid tool for quality assurance, both in detecting systematic errors which may escape the data transfer/MU calculation check and in giving an effective way of estimating the accuracy of treatment delivery.

In vivo dosimetry: intercomparison between p-type based and n-type based diodes for the 16-25 MV energy range

This paper compares two different types of diodes designed to cover the energy range from 16 to 25 MV, one n-type (diode-A) and the other p-type (diode-B). A 18 MV x-ray beam has been used for all tests. Signal stability postirradiation, intrinsic precision and linearity of response with dose, front-back symmetry, and dose decrease under the diode were studied. Also, the water equivalent thickness of the build up caps was determined. Both types of diodes were calibrated to give entrance dose. Entrance correction factors for field size, tray, source skin distance, angle, and wedge were determined. Finally, the effect of dose rate, temperature and accumulated dose on the diode's response were studied. Only diode-A had full build-up for 18 MV x rays and standard irradiation conditions. Field size correction factor was about 2%-4% for field sizes bigger than 20 x 20 cm2 for both diodes. Tray correction factor was negligible for diode-A while diode-B would overestimate the dose by a 2% for a 40 x 40 cm2 field size if the correction factor was not applied. Wedge correction factors are only relevant for the 60 degrees wedge, being the correction factor for diode-A significantly higher than for diode-B. Diode-A showed less temperature dependence than diode-B. Sensitivity dependence on dose per pulse was a 1.5% higher for diode-A than for diode-B and therefore a higher SSD dependence was found for diode-A. The loss of sensitivity with accumulated radiation dose was only about 0.3% for diode-A, after 300 Gy, while it amounted to 8% for diode-B. Weighing the different correction factors for both types of diodes no conclusions about which type is better can be driven. From these results it can be also seen that the dependence of the diode response on dose rate in a pulsed beam does not seem to be associated with the fact of being n-type or p-type but could be related to the doping level of the diodes.

Entrance dose measurements for in-vivo diode dosimetry: Comparison of correction factors for two types of commercial silicon diode detectors

Silicon diode dosimeters have been used routinely for in-vivo dosimetry. Despite their popularity, an appropriate implementation of an in-vivo dosimetry program using diode detectors remains a challenge for clinical physicists. One common approach is to relate the diode readout to the entrance dose, that is, dose to the reference depth of maximum dose such as d(max) for the 10x10 cm(2) field. Various correction factors are needed in order to properly infer the entrance dose from the diode readout, depending on field sizes, target-to-surface distances (TSD), and accessories (such as wedges and compensate filters). In some clinical practices, however, no correction factor is used. In this case, a diode-dosimeter-based in-vivo dosimetry program may not serve the purpose effectively; that is, to provide an overall check of the dosimetry procedure. In this paper, we provide a formula to relate the diode readout to the entrance dose. Correction factors for TSD, field size, and wedges used in this formula are also clearly defined. Two types of commercial diode detectors, ISORAD (n-type) and the newly available QED (p-type) (Sun Nuclear Corporation), are studied. We compared correction factors for TSDs, field sizes, and wedges. Our results are consistent with the theory of radiation damage of silicon diodes. Radiation damage has been shown to be more serious for n-type than for p-type detectors. In general, both types of diode dosimeters require correction factors depending on beam energy, TSD, field size, and wedge. The magnitudes of corrections for QED (p-type) diodes are smaller than ISORAD detectors.

A method to estimate the transit dose on the beam axis for verification of dose delivery with portal images

PURPOSE AND BACKGROUND

A feasibility study is performed to evaluate the possibility of using the transit dose of portal images on the beam axis to measure the accuracy in dose delivery. The algorithm and the method are tested on a breast phantom and on patients with a breast disease.

MATERIALS AND METHODS

To estimate the transit dose at various air gaps behind the patient, a method is proposed which applies, for a given air gap, the inverse square law to the primary component of the exit dose and an experimentally determined function for the scatter component of the exit dose. It is assumed that the primary component and the scattered component of the exit dose are given by the treatment planning system. The experimental function for the variation of the scattered component with the air gap, determined by phantom measurements, is modelled by an analytical function which contains only field size, air gap and one energy-dependent parameter.

RESULTS

The measurements on the breast phantom yield a maximum deviation between measured and estimated transit doses of 4.5%. The mean deviation is 0.9% with a standard deviation of the distribution of 2.3%. In vivo diode measurements on the same phantom yield a maximum deviation of 2.7%. Transit dose measurements on the beam axis for 45 portal images of breast patients show a mean deviation of 0.0% between the measured transit dose and the estimated transit dose. The standard deviation of the distribution is 4.4%. The method seems to be very sensitive to patient positioning and to discrepancies in breast thicknesses used for treatment planning.

CONCLUSION

Preliminary results on breast patients show that the method proposed to evaluate transit doses on the beam axis from portal images may be a valuable alternative to conventional in vivo exit dosimetry. The method can be implemented in a simple way and does not require additional time during the irradiation session, as exit dosimetry with diodes does. The transit dose is only considered in one point. Nevertheless, in the framework of quality assurance of treatment delivery, this study is an example of the possibilities of monitoring at the same time the visual evaluation of the irradiated volume as well as the dosimetric control (i.e. in Gy) of treatment delivery with portal images.